Want to see IN:VENUSREM full AI Analyst Report?

Venus Remedies Limited (VENUSREM) Price & Analysis

1 Followers

VENUSREM Stock Chart & Stats

₹1650.60

-₹77.00(-4.67%)

At close: Jul 27 4:00 PM EDT

₹1650.60

-₹77.00(-4.67%)

Day’s Range― - ―

52-Week Range₹432.00 - ₹2,043.15

Previous CloseN/A

Volume69.99K

Average Volume (3M)3.15K

Market Cap

₹23.85B

Enterprise Value₹10.13B

Total Cash (Recent Filing)₹1.03B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)20.8

Beta0.85

Next Earnings

Nov 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.56%

Share Statistics

EPS (TTM)86.91

Shares Outstanding13,366,988

10 Day Avg. Volume4,816

30 Day Avg. Volume3,150

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)1.65

Price to Sales (P/S)1.42

P/FCF Ratio9.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)39.9

Revenue Forecast (FY)₹828.20M

Bulls Say, Bears Say

Bulls Say

Improving Revenue TrendA return to consistent revenue growth indicates improving demand and market execution across the company’s pharmaceutical portfolio. Sustained top-line expansion can support operating leverage, strengthen the company’s market position, and provide a durable base for future earnings growth.

Strong Profitability ImprovementThe substantial increase in net income and EBIT shows that Venus Remedies materially improved earnings capacity in the latest period. If operating performance remains supported by revenue growth, the stronger profit base can fund reinvestment, reinforce resilience, and improve long-term returns.

Low Leverage And Strong Cash GenerationVery low leverage gives the company financial flexibility and reduces the burden of interest or refinancing obligations. The latest rise in operating and free cash flow further improves internally generated funding capacity, allowing Venus Remedies to support operations and growth without relying heavily on external capital.

Bears Say

Uncertain Margin SustainabilityThe absence of clear 2026 margin detail makes it difficult to determine how much of the earnings surge reflects durable operating improvement. Material historical gross-margin fluctuations also suggest that product mix or operating conditions may affect profitability, limiting confidence in sustained margins over coming quarters.

Uneven Cash ConversionUneven conversion of accounting profits into operating cash can make funding capacity less predictable even when reported earnings are strong. This pattern may require closer management of working capital and capital expenditure, potentially reducing the consistency of cash available for expansion or other long-term priorities.

Volatile Absolute Debt LevelsAlthough overall leverage remains low, fluctuations in absolute debt indicate that financing needs have not been entirely stable. If borrowing rises alongside uneven cash conversion, financial flexibility could narrow and the company may have less room to absorb operational volatility or pursue investments from internally generated funds.

Venus Remedies Limited News

Venus Remedies Secures Shareholder Approval for All Resolutions at 37th AGM

An update from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has announced that...

2M ago

Venus Remedies Publishes 37th AGM Notice in Compliance Filing

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an announcement. Venus Remedies Limited has notified the stock exchange...

2M ago

Venus Remedies Clears FY26 Results, Declares Final Dividend and Strengthens Governance

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an announcement. Venus Remedies Limited reported its audited financial results...

4M ago

Venus Remedies Posts FY26 Results, Sets AGM and Dividend, Strengthens Governance

Venus Remedies Limited ( ($IN:VENUSREM) ) has issued an update. Venus Remedies Limited reported its financial results for...

4M ago

Venus Remedies Declares Final Dividend and Sets August Virtual AGM

The latest update is out from Venus Remedies Limited ( ($IN:VENUSREM) ). Venus Remedies Limited has reported its...

4M ago

Venus Remedies Opens Special Window for Physical Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an announcement. Venus Remedies Limited has notified the stock exchange...

5M ago

Venus Remedies Alerts Shareholders to Special Window for Physical Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) just unveiled an update. Venus Remedies has notified stock exchanges that it...

7M ago

Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers

An announcement from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has notified the...

8M ago

Venus Remedies Closes Trading Window Ahead of December 2025 Results

Venus Remedies Limited ( ($IN:VENUSREM) ) has issued an update. Venus Remedies Limited has announced that, in accordance...

10M ago

Venus Remedies Opens Special Window for Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has announced the opening of...

10M ago

VENUSREM FAQ

What was Venus Remedies Limited’s price range in the past 12 months?

Venus Remedies Limited lowest stock price was ₹432.00 and its highest was ₹2043.15 in the past 12 months.

What is Venus Remedies Limited’s market cap?

Venus Remedies Limited’s market cap is ₹23.85B.

When is Venus Remedies Limited’s upcoming earnings report date?

Venus Remedies Limited’s upcoming earnings report date is Nov 14, 2026 which is in 40 days.

How were Venus Remedies Limited’s earnings last quarter?

Venus Remedies Limited released its earnings results on Jul 20, 2026. The company reported ₹17.184 earnings per share for the quarter.

Is Venus Remedies Limited overvalued?

According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Venus Remedies Limited pay dividends?

Venus Remedies Limited pays a Notavailable dividend of ₹10 which represents an annual dividend yield of 0.56%. See more information on Venus Remedies Limited dividends here

What is Venus Remedies Limited’s EPS estimate?

Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Venus Remedies Limited have?

Venus Remedies Limited has 13,366,988 shares outstanding.

What happened to Venus Remedies Limited’s price movement after its last earnings report?

Venus Remedies Limited reported an EPS of ₹17.184 in its last earnings report. Following the earnings report the stock price went down -4.564%.

Which hedge fund is a major shareholder of Venus Remedies Limited?

Currently, no hedge funds are holding shares in IN:VENUSREM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Venus Remedies Limited

Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spectrum of therapeutic areas, including treatments for pain and fever, diabetes, bacterial infections, cardiovascular conditions, gastrointestinal disorders, neurological ailments, and oncology. Additionally, it provides solutions for respiratory health, skin and wound care, stress management, and urological issues, alongside essential vitamins, minerals, and nutritional supplements. Venus Remedies is also active in the field of antimicrobial resistance, offering specialized products, and it supplies disinfectants and hand sanitizers. Furthermore, the firm maintains a distinct line of herbal products and offers hormones and iron supplements. Established in 1989, Venus Remedies Limited operates from its headquarters in Panchkula, India.